To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane-and cisplatinum-based chemotherapy as first-line. We retrospectively studied prospectively collected parameters from 131 consecutive patients with metastatic ACC (44 with a tissue specimen available) treated at the Gustave Roussy Institute with mitotane-and platinum-based chemotherapy. Fifty-five patients with clinical, pathological, and morphological data available together with treatment characteristics including detailed follow-up were enrolled. Plasma mitotane levels and ERCC1 protein staining were analyzed. Response was analyzed according to RECIST criteria as well as overall survival (OS) from the start of cisplatinum-based chemotherapy. Parameters impacting on OS were evaluated by univariate analysis, and then analyzed by multivariate analysis. Using a landmark method, OS according to response to chemotherapy was analyzed. Objective response to combined mitotaneand cisplatinum-based chemotherapy was 27.3%. Median OS was 1 year. In the univariate analysis, resection of the primary, time since diagnosis, mitotane monotherapy as single first-line treatment, number of affected organs, plasma mitotane above 14 mg/l, and objective response were predictors of survival. In the multivariate analysis, mitotane level R14 mg/l and objective response to platinum-based chemotherapy were found to be independent predictors of survival (PZ0.03 and !0.001). Our study suggests a prognostic role for mitotane therapy and objective response to platinum-based chemotherapy.
Introduction
Adrenocortical carcinoma (ACC) is one of the most aggressive solid tumors, as highlighted by a 5-year survival rate of below 13% in patients with distant metastases (Icard et al. 2001 , Berruti et al. 2005 In 2010, surgery is the only curative therapeutic modality in localized ACC (Allolio & Fassnacht 2006) . In case of inoperable ACC, mitotane combined with cisplatinum has been demonstrated to yield objective responses but their impact on survival is still debated (Gicquel et al. 1997 , Allolio & Fassnacht 2006 , Phan 2007 , Fareau et al. 2008 , Veytsman et al. 2009 ). Multiagent chemotherapy combining platinum with doxorubicin-etoposide or streptozotocin has yielded the highest objective response rates (Khan et al. 2000 , Berruti et al. 2005 , and was the basis for the first international randomized FIRMACT trial (http://clinicaltrials.gov/ct2/show/NCT00094497). New agents based on the validation of new molecular targets (Barlaskar et al. 2009 , Carden et al. 2009 , Nakamura et al. 2009 ) but also better prediction of the activity of drugs that have long been used in ACC (Haak et al. 1994 , Baudin et al. 2001 , Olaussen et al. 2006 , Ronchi et al. 2009 ) can be considered as urgently needed.
A plasma mitotane level above 14 mg/l but also ERCC1 staining has both been proposed as predictors of response to mitotane-or cisplatinum-based therapies respectively (Haak et al. 1994 , Baudin et al. 2001 , Ronchi et al. 2009 . Indeed, ACC patients with an elevated serum mitotane level (O14 mg/l) have been reported to achieve a 55-66% objective response rate versus no response when mitotane levels remained below 14 mg/l (Haak et al. 1994 , Baudin et al. 2001 . Recently, low ERCC1 expression, ERCC1 being a marker of the presence of a DNA repair complex within tumor cells, was shown to be associated with efficacy of cisplatinum therapy in several cancers including lung, ovarian, and colorectal cancer (Dabholkar et al. 1994 , Shirota et al. 2001 , Lord et al. 2002 , Olaussen et al. 2006 but also ACC patients (Ronchi et al. 2009) .
A retrospective analysis was undertaken in a population of patients with metastatic ACC treated with first-line mitotane-and platinum-based chemotherapy and followed up in a single tertiary care referral center with two main goals: first to search for prognostic markers, including objective response, of overall survival (OS) after combined mitotane-and cisplatinum-based chemotherapy and, second to confirm the interest of plasma mitotane level monitoring and ERCC1 staining. To this end, all recently individualized prognostic parameters in patients with ENSAT stages III and IV ACC were cautiously analyzed (Bukowski et al. 1993 , Abraham et al. 2002 , Berruti et al. 2005 , Assie et al. 2007 , Ronchi et al. 2009 ).
Materials and methods

Patients and combined mitotane-and platinum-based chemotherapy
Patients with a diagnosis of ACC referred for treatment to the Gustave Roussy Institute from January 1993 to March 2007 were retrospectively screened. Inclusion criteria were as follows: 1) pathological review of ACC, including Weiss score evaluation, 2) unresectable European network for the study of adrenal tumors tumor-node-metastasis (ENSAT-TNM) stages III or IV disease, 3) at least one cycle of first-line platinumbased chemotherapy combined or not with mitotane therapy, 4) the entire follow-up at the Gustave Roussy Institute including plasma mitotane measurement and chest and abdominal computed tomography (CT) scan imaging evaluation before chemotherapy, and then every 2 months during chemotherapy and every 3-4 months thereafter.
For more than 15 years, patients with inoperable ACC in our institution have received mitotane as a single first-line therapeutic option with the aim of achieving a therapeutic plasmatic concentration of between 14 and 20 mg/l, as previously reported (Baudin et al. 2001 , Faggiano et al. 2006 . Platinum-based chemotherapy was administered in case of disease progression under mitotane therapy or combined with mitotane in case of rapidly progressive disease before treatment or a bulky tumor burden (Schlumberger et al. 1991 , Bonacci et al. 1998 . The initial chemotherapy regimens and drug doses were as follows: cisplatin 100 mg/m 2 in 1 or 3 daysC etoposide 100 mg/m 2 , days 1-3 every 4 weeks or carboplatin (according to the Calvert formula)C etoposide 100 mg/m 2 , days 1-3, again every 4 weeks. Chemotherapy was maintained until disease progression, persistent nonhematological grades 3-4 toxicity or patient's refusal. Cycles were delayed or doses reduced if grades 2-4 toxicity failed to resolve.
Data collection
The following parameters were recorded in all patients: gender, age, hormone secretion, defined as the presence or not of clinical symptoms related to steroid secretions, the type of hormonal secretion, ENSAT stage at chemotherapy initiation ), previous therapeutic options including primary surgery and completeness of surgical resection (R0, R1/2, and Rx), delay between diagnosis of ACC, and initiation of platinum-based therapy (median and cutoff at 6 months), Weiss score (median and cut-off at 6), mitotic count within the primary tumor (cut-off at 20 per 50 high-power field), number of diseased organs (cut-off at 2), mitotane monotherapy as single first-line treatment (yes or no), and plasma mitotane level at the time of initiation of platinum-based therapy (cut-off at 14 mg/l). The number of cycles including full-dose cycles was also recorded. In addition, ERCC1 staining was performed in a subgroup of 44 patients including 33 patients with all collected data available as described in the section.
Immunostaining for ERCC1 and microscopic analysis
A tissue block was available for 44 patients (39 surgical samples and 5 biopsy specimens), and analyzed before chemotherapy initiation. The entire specimen was analyzed by an expert pathologist (A A G) blinded to clinical data. We used a standard protocol for immunostaining of samples. In brief, for epitope retrieval, specimens were exposed to 10 mM citrate buffer (pH 6.0) and heated for 20 min in a water bath. Tumor sections were incubated for 60 min with a monoclonal antibody raised against the full-length human ERCC1 protein at a 1:100 dilution (mouse, clone 8F1, Neomarker, Lab Vision, Fremont, CA, USA). Antibody binding was detected using an ABC kit with NovaRED as the substrate (Vectastain Elite, Vector Laboratories, Burlingame, CA, USA) and Mayer's hematoxylin as the counterstain. Sections of normal tonsil tissues were included as external positive controls (Olaussen et al. 2006) , and stromal cells surrounding the tumor served as internal positive controls. The investigator, who evaluated ERCC1 staining under a light microscope at a magnification of 400!, recorded whether tumor or stromal cells expressed ERCC1. Only samples with positive ERCC1 staining in the nucleus were deemed positive. Staining intensity was graded on a scale of 0-3 (with a higher number indicating a higher intensity and with endothelial cells used as a reference and assigned an intensity of 2). The percentage of positive tumor nuclei was estimated semiquantitatively for each specimen, and a proportion score was assigned (0 if 0%, 0.1 if 1-9%, 0.5 if 10-49%, and 1.0 if 50% or more), as previously described (Olaussen et al. 2006) . This proportion score was multiplied by the staining intensity of nuclei to obtain a final semiquantitative H-score. In accordance with the above-referenced publication, an H-score O1 was a priori chosen as the cut-off point for separating samples with high ERCC1 (ERCC1-high) or low ERCC1 (ERCC1-low) expression. ERCC1 staining intensity (ascribed as high if equal to 3 or low if below 3) was also analyzed in this study.
Response evaluation
A chest and abdominal CT with contrast agent injection were performed prospectively in all patients within 4 weeks before chemotherapy initiation and every 2 months during the course of treatment. Subsequently, a chest and abdominal CT were performed every 3-4 months during follow-up. In addition, a bone scan was regularly performed. The best response was defined according to RECIST criteria (Therasse et al. 2000) based on the sum of the longest diameters of target lesions, the recording of nontargeted lesions and an assessment of new lesions. Briefly, complete (CR) or partial (PR) response to platinum was defined as the disappearance of any detectable morphological disease or a decrease in tumor burden exceeding 30% respectively; progressive disease was defined as a tumor burden increase exceeding 20% or the appearance of new lesions; otherwise, the tumor was classified as stable disease. All images were prospectively analyzed at the time of treatment, and reviewed for the present study by two investigators (P M and C D). A consensus was reached in all cases. The best response obtained under platinum therapy was recorded in all patients. The mitotane level was monitored in patients using the HPLC method, in our institution (Baudin et al. 2001) or more recently by PAREXEL (rZ0.98 between both methods as assessed in 45 consecutive patients in 2007). The mitotane level at the time of the best tumor response was also recorded.
Statistical analysis and landmark method
The median and range are provided for quantitative data, whereas numbers and percentages are used for qualitative data. Percentages were compared using the c 2 test, and the t-test was used for continuous variables. November 1st, 2008 was the date of the last follow-up for the censored data analysis. The endpoint of our study was OS after the initiation of cisplatinum-based chemotherapy (time between cisplatinum initiation and death from any cause or the date of the last visit). Response to chemotherapy was analyzed through logistic regression, and the results are reported with the odds ratio and 95% confidence intervals (CI). OS was calculated using the Kaplan-Meier method (Kaplan & Meier 1958 ) and Rothman's 95% CI (Rothman 1978) . All tests are two-sided. Univariate and multivariate analyses were performed using the logrank test and Cox models (Cox 1972) . The results of the Cox model analysis are reported with relative risks and the 95% CI. Variables with a P value below 0.1 were retained in the multivariate analyses. A landmark Endocrine-Related Cancer (2010) 17 797-807 www.endocrinology-journals.org method (Simon 1989 ) was used to determine survival from 2 months after the initiation of therapy to provide an unbiased conditional estimate of the response and OS. In fact, the time origin is shifted to the right with this method, so that response can be considered as any other prognostic factor known at the origin of survival time. The level of significance chosen was the conventional 5% (0.05). Statistical analyses were performed with the SAS software, version 9.1 (SAS_Institute 1999, SAS, Cary, NC, USA).
Results
Clinical and therapeutic characterization of the population under study One hundred and thirty-one patients (46 males and 85 females) were seen during the study period (Table 1) . After a careful appraisal of the clinical data collected, 76 were finally excluded: 10 patients did not fulfill the first inclusion criterion (pathological review of ACC), 14 patients did not fulfill the second inclusion criterion (unresectable ENSAT-TNM stages III or IV disease), 31 patients did not fulfill the third inclusion criterion (at least one cycle of first-line platinum-based chemotherapy combined or not with mitotane therapy), and 21 patients did not fulfill the fourth inclusion criterion (entire follow-up at the Gustave Roussy Institute including plasma mitotane measurement and imaging evaluation). Thus, 55 patients with ACC constituted the study population.
The main characteristics of the population under study compared with the excluded population are described in Table 1 . In the 55 patients, platinum-based chemotherapy was given together with mitotane at the time of treatment initiation in 11 patients or administered in case of disease progression under mitotane therapy in 44 patients, including 15 patients with at least one plasma mitotane level above 14 mg/l within the month prior chemotherapy. Initially, 50 patients were given the cisplatinum regimen, and five patients were given the carboplatin regimen (see Materials and methods). In addition, 10 out of 50 patients first treated with cisplatinum, received carboplatin as second-line therapy due to cisplatinum-induced toxicity or to maintain or improve the tumor response after six cycles of cisplatinum therapy. The dose was reduced in nine patients, delayed in ten patients but never discontinued due to toxicity. Subsequently, various treatment options were administered including other chemotherapies (31 patients) and loco-regional therapy in 24 patients including surgery in four patients. 
Overall survival
At the time of the analysis, 50 patients had died, and five were still alive. Median disease-free interval between first treatment of the ACC and the diagnosis of metastasis was 2.8 months (rangeZ0-24.1).
The median delay between diagnosis of ACC and platinum-based therapy was 11 months (range Z0.3-120.4 months). The median delay between the diagnosis of metastasis and platinum-based therapy was 5 months (rangeZ0.2-120.4 months).
Median OS after the initiation of cisplatinum-based chemotherapy was 1 year (rangeZ18 days-11 years). OS was O6 months, 1 year, or 2 years in 42 (76.4%), 27 (49.1%), and 11 (20%) patients respectively.
Prognostic parameters for OS after initiation of mitotane-and platinum-based chemotherapy The parameters analyzed are described in the section data collection and in Table 2 (Fig. 1) . In the univariate analysis, resection of the primary tumor (hazard ratio (HR)Z3.77, 95% CIZ(1.39-10.2), PZ0.009), the number of metastatic organs (HRZ2.97, 95% CIZ(1.51-5.86), PZ0.002), time between diagnosis of ACC and initiation of cisplatinum therapy (HRZ0.52, 95% CIZ(0.28-0.96), PZ0.04), mitotane monotherapy as single first-line treatment (HRZ0.42, 95% CI Z(0.21-0.84), PZ0.014), plasma mitotane O14 mg/l (HRZ0.51, 95% CIZ(0.25-1.05), PZ0.07), and objective response to cisplatinum-based chemotherapy (HRZ4.19, 95% CIZ(1.99-8.83), P!0.0001) were predictive for OS. Median OS was 13.5 and 7.7 months in patients who underwent or not surgical resection of the primary tumor respectively. Median OS was 15.6 and 7.1 months in patients with fewer than 2 or 2 or, more than 2 diseased organs respectively. Median OS was 13.3 and 7.6 months in patients with a time interval between the diagnosis of ACC and initiation of cisplatinum of 6 or more months or below 6 months respectively. Median OS was 13.3 and 4.0 months respectively in patients who received mitotane therapy as a single first-line or not respectively. Median OS was 19.6 and 9.5 months for patients with a mitotane level R14 and !14 mg/l respectively (Fig. 1A) . Lastly, median OS for responders to cisplatinumbased chemotherapy was 40.6 months, whereas it was 9.6 months in nonresponders (Fig. 1B) . In the multivariate analysis, the objective response to cisplatinum-based chemotherapy (HRZ5.55, 95% CIZ(2.06-14.96), P!0.001) and the mitotane level R14 mg/l (HRZ0.35, 95% CIZ(0.14-0.89), PZ0.03) were found to be independent prognostic factors for survival after platinum-based chemotherapy (Table 2 ). According to the absence of the presence of one or two of these independent prognostic factors, median survival was 35.6 months for patients with none of them, and 19.7 months and 7.1 months for patients with one or two respectively (log-rank P value for trend !0.0001; Fig. 1C ).
ERCC1 expression in ACC
Among the 44 patients in whom the ERCC1 H-score was analyzed, 21 (47%) had an H-score below 1. The characteristics of ACC patients with a low ERCC1 H-score (ERCC1-low) compared with a high ERCC1 H-score (ERCC1-high) are described in Table 3 . No major differences were observed between patients with a high or low ERCC1 H-score. Thirty-three of these 44 patients fulfilled inclusion criteria: 3 out of 18 patients (16.7%) with ERCC1-high and 4 out of 15 patients (26.7%) with ERCC1-low achieved an objective response (PZ0.48). Median OS in ERCC1-low patients was 13.3 months, and median OS in ERCC1-high patients was 10.1 months (not significant). The same analysis taking into account ERCC1 staining intensity showed that an objective response was observed in 1 out of 11 patients (9.1%) expressing a high-intensity staining score of 3 and in 6 out 22 patients (27.3%) expressing a lowintensity staining score of !3. Median OS in patients with ERCC1-low intensity was 14.5 months and 7.6 months in patients with ERCC1-high intensity (not significant). 
Discussion
Progress in the field of ACC has generally been considered limited over the recent decades because the magic bullet targeting the magic target is still awaited. This should not however overlook the fact that progress has been made in the definition of prognostic parameters of ACC and in predictors of response (Haak et al. 1994 , Baudin et al. 2001 , Stojadinovic et al. 2002 , Berruti et al. 2005 , Abiven et al. 2006 , Assie et al. 2007 ). Prognostic studies enable the evaluation of various strategies in homogeneous prognostic subgroups of ACC patients. The latter set of data allows one to tailor therapeutic options to a given tumor in a given patient. In agreement with the landmark method, patients who die (nZ7 pts) before the landmark time point were excluded, making a total number of 48 patients available for statistical analysis.
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Finally, the first randomized study ever conducted has been set up, indicating the involvement of networks in this rare cancer. In the field of cytotoxic chemotherapy, apart from mitotane therapy, cisplatinum is considered the drug of choice but is certainly not efficient enough. In this study, combined first-line therapy with mitotane-and cisplatinum-based chemotherapy allowed a 27% objective response rate, which is in the range of previous reports (van Slooten et al. 1984 , Schlumberger et al. 1991 , Bukowski et al. 1993 , Berruti et al. 1998 , Bonacci et al. 1998 , Williamson et al. 2000 , Abraham et al. 2002 . Owing to the combination with mitotane therapy in most studies, the exact antitumor role of cisplatinum-based chemotherapy remains uncertain. In addition, the delayed activity of mitotane skewed a proper analysis of the antitumor role of other drugs (Veytsman et al. 2009 ).
To the best of our knowledge, four published studies have pursued a similar objective, which was to highlight prognostic parameters of ACC patients at the time of chemotherapy initiation (Bukowski et al. 1993 , Abraham et al. 2002 , Berruti et al. 2005 , Ronchi et al. 2009 ). In addition, one study previously analyzed prognostic parameters of stage IV ACC patients at the time of metastatic disease discovery (Assie et al. 2007) . We found surgery of the primary, number of metastatic organs, time between diagnosis of ACC and cisplatinum initiation, mitotane monotherapy as single first-line treatment, plasma mitotane level above 14 mg/l, and an objective response to chemotherapy to provide with the most powerful prognostic information. The two latter parameters remained significant at multivariate analysis. As a general consideration, whether parameters highlighted in our studies should be considered as prognostic parameters or predictors of response cannot be drawn from our study, and awaits further validation in randomized studies.
Although rarely investigated in previous studies, the prognostic impact of the resection of the primary has also been retrieved in two previous studies (Bukowski et al. 1993 , Icard et al. 2001 . This finding suggests a role for primary related local morbidity and therefore a role for primary surgery even in selected metastatic ACC patients. However, the fact that only five patients did not undergo primary surgery in our study precludes a definite conclusion. In contrast, the R status seems to play a minor role in our study in contrast with recent data (Abraham et al. 2002 , Bilimoria et al. 2008 . One explanation could be that the prognostic role of the R status may be mainly related to potentially curable stages I-II ACC patients. Our study confirms a prognostic role of the number of diseased organs at Endocrine-Related Cancer (2010) 17 797-807
www.endocrinology-journals.org the time of chemotherapy initiation, as highlighted in two prognostic studies performed in unresectable stages III-IV ACC (Berruti et al. 2005 , Assie et al. 2007 . Together, these results suggest that tumor burden at the time of chemotherapy initiation could be a critical parameter. A higher survival rate was found in patients with time between diagnosis of ACC and initiation of cisplatinum longer than 6 months, as already found by other teams (Berruti et al. 2005) . This parameter may simply reflect a lower aggressiveness of the disease but also that this first-line chemotherapy is not active in rapidly progressive disease. The absence of prognostic information related to high mitotic index may be interpreted in the same way. A prognostic impact of mitotane therapy in metastatic ACC patients has been suggested by several prognostic studies (Icard et al. 2001 , Kendrick et al. 2001 , Abiven et al. 2006 but not all (Venkatesh et al. 1989) . In addition, the prognostic influence of plasma mitotane levels above 14 mg/l has been previously reported in two studies (Haak et al. 1994 , Wangberg et al. 2010 but not in all (Abraham et al. 2002) . Our study reinforces the role of mitotane therapy in ACC patients when plasma level above 14 mg/l can be reached. Interestingly, responses were observed in patients with progressive disease even in those who did or did not experience at least one plasma level above 14 mg/l prior chemotherapy initiation. This result may suggest either an impact of combined platinum-based chemotherapy or, the need for prolonged period of high plasma level of mitotane to achieve antitumor effect. With respect to this comment, the understanding of the prognostic influence of mitotane therapy started as first-line at univariate analysis is not straightforward. Such strategy may confer a greater chance to rapidly achieve therapeutic plasma level of mitotane hampering cumulative digestive toxicity of both mitotane and cytotoxic chemotherapy. An alternative hypothesis could be that this parameter identifies a subgroup of patients with lower aggressiveness allowing time to initiate mitotane therapy. In the absence of randomized trial to solve this issue, we advocate to maintain mitotane therapy as long as the tolerance is acceptable until at least two plasma levels above 14 mg/l, 2 months apart, are reached.
We confirm the prognostic impact of chemotherapyrelated objective response, as previously suggested (Abraham et al. 2002 , Berruti et al. 2005 , Gonzalez et al. 2007 . Objective response was the most significantly correlated parameter with OS: a remarkable median OS of 40.6 months was observed in patients experiencing an objective response. This OS is clearly longer than the 10-28 months median OS reported in previous studies (Decker & Kuehner 1991 , Bukowski et al. 1993 , Williamson et al. 2000 , Abraham et al. 2002 , Berruti et al. 2005 ) suggesting a survival benefit of therapy in this subgroup of ACC patients. Since for the first time all individualized prognostic parameters and predictors of response individualized to date were included in the statistical analysis, we hypothesize that biases related to confounding prognostic parameters are decreased. Objective response to combined mitotane-and platinum-based chemotherapy may therefore be considered as a surrogate marker for survival in ACC patients, and this has to be confirmed in future randomized studies. Finally, these results suggest that ACC patients in whom therapeutic mitotane plasma level above 14 mg/l cannot be attained or in whom objective response is not achieved within the initial phase of therapy should be proposed alternative therapeutic strategy. Recently, using tissue microarray analysis, Ronchi et al. were the first to report that ERCC1 staining was the strongest predictor of survival after the initiation of cisplatinum in 45 ACC patients. In that study, low staining for ERCC1 was indicative of a higher response rate observed in 29% of ACC patients versus 14% when ERCC1 staining was high, with the most significant impact on survival. Using the same methodology, we found a similar response rate (26.7 vs 16.7% in ERCC1-low and -high patients respectively) but ERCC1 staining had no influence on survival after platinum-based chemotherapy. Multiple reasons may explain these discrepancies, the most important being that one cannot predict whether a tumor response in ACC is due to cisplatinum-based chemotherapy alone or combined with mitotane therapy. These discrepancies may also be related to the lower number of cases analyzed in our series. However, our study includes additional data like the measurement of plasma mitotane level in the vast majority of patients, RECIST review, and internal quality control for ERCC1 staining, which may also affect the general conclusion. One cannot exclude the possibility that other methodological approach for ERCC1 analysis or other molecular partners involved in DNA repair might be interfering (Siddik 2003) .
In conclusion, in metastatic ACC patients, in the absence of an established treatment protocol, combined mitotane-and cisplatinum-based chemotherapy could be considered an acceptable first-line treatment option if plasma mitotane level above 14 mg/l is obtained and or an objective response demonstrated within the initial phase of treatment.
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